We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Agios Pharmaceuticals
AGIO
$1.91B
| $7.75M | 0.04% |
233,068
+212,687
| +1,044% | +$6.45M |
|
477
Immunocore
IMCR
$1.75B
| $7.74M | 0.04% |
246,498
-81,747
| -25% | -$2.54M |
|
478
Arbutus Biopharma
ABUS
$897M
| $7.72M | 0.04% |
2,497,984
-157,754
| -6% | -$524K |
|
479
Amylyx Pharmaceuticals
AMLX
$2.69B
| $7.69M | 0.04% |
1,200,290
-409,157
| -25% | -$1.99M |
|
480
Carpenter Technology
CRS
$27.7B
| $7.64M | 0.04% |
27,655
+5,304
| +24% | +$1.16M |
|
481
US Bancorp
USB
$99.4B
| $7.63M | 0.04% |
168,530
+36,733
| +28% | +$1.54M |
|
482
Absci
ABSI
$1.41B
| $7.62M | 0.04% |
2,966,106
+1,574,861
| +113% | +$4.43M |
|
483
Motorola Solutions
MSI
$78.7B
| $7.59M | 0.04% |
18,055
+3,936
| +28% | +$1.65M |
|
484
Analog Devices
ADI
$184B
| $7.51M | 0.04% |
31,553
-129,998
| -80% | -$27.1M |
|
485
Ashland
ASH
$3.32B
| $7.48M | 0.04% |
+148,713
| New | +$7.56M |
|
486
Dianthus Therapeutics
DNTH
$6.15B
| $7.46M | 0.04% |
400,504
+100,000
| +33% | +$1.88M |
|
487
Travere Therapeutics
TVTX
$5.89B
| $7.41M | 0.04% |
500,995
-728,783
| -59% | -$12.1M |
|
488
Legend Biotech
LEGN
$3.73B
| $7.28M | 0.04% |
205,077
+91,106
| +80% | +$2.95M |
|
489
Edgewell Personal Care
EPC
$1.3B
| $7.28M | 0.04% |
310,799
+225,722
| +265% | +$6.26M |
|
490
CRISPR Therapeutics
CRSP
$4.99B
| $7.26M | 0.04% |
149,267
+12,784
| +9% | +$495K |
|
491
Lantheus
LNTH
$6.6B
| $7.24M | 0.04% |
88,397
| – | – |
|
492
Cogent Biosciences
COGT
$7.14B
| $7.18M | 0.04% |
1,000,611
-686,929
| -41% | -$3.81M |
|
|
AXON
493
Axon Enterprise
AXON
$42.1B
| $7.16M | 0.04% |
8,643
+1,711
| +25% | +$1.16M |
|
494
Vistra
VST
$47.7B
| $7.11M | 0.04% |
36,706
+7,962
| +28% | +$1.18M |
|
|
BNY
495
Bank of New York Mellon
BNY
$108B
| $7.05M | 0.04% |
77,387
+16,754
| +28% | +$1.42M |
|
496
Intuit
INTU
$88.1B
| $7.04M | 0.04% |
+8,942
| New | +$6.05M |
|
497
Northern Oil and Gas
NOG
$2.21B
| $7.03M | 0.04% |
247,990
+8,745
| +4% | +$235K |
|
498
EverCommerce
EVCM
$1.88B
| $7.02M | 0.04% |
668,820
+108,314
| +19% | +$1.09M |
|
499
Cytokinetics
CYTK
$11B
| $7.01M | 0.04% |
212,303
| – | – |
|
500
Newmont
NEM
$111B
| $7.01M | 0.04% |
120,393
+24,211
| +25% | +$1.29M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.